Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

被引：71

作者：

Amara, RR

Villinger, F

Altman, JD

Lydy, SL

O'Neil, SP

Staprans, SI

Montefiori, DC

Xu, Y

Herndon, JG

Wyatt, LS

Candido, MA

Kozyr, NL

Earl, PL

Smith, JM

Ma, HL

Grimm, BD

Hulsey, ML

McClure, HM

McNicholl, JM

Moss, B

Robinson, HL

机构：

[1] Emory Univ, Vaccine Res Ctr, Yerkes Reg Primate Res Ctr, Atlanta, GA 30329 USA

[2] Emory Univ, Sch Med, Vaccine Res Ctr, Dept Pathol & Lab Med, Atlanta, GA 30322 USA

[3] Emory Univ, Sch Med, Vaccine Res Ctr, Dept Microbiol & Immunol, Atlanta, GA 30322 USA

[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA

[5] NIAID, NIH, Viral Dis Lab, Bethesda, MD 20892 USA

[6] Emory Univ, Sch Med, Vaccine Res Ctr, Div Infect Dis,Dept Med, Atlanta, GA 30322 USA

[7] Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, Ctr Dis Control & Prevent, Atlanta, GA 30330 USA

来源：

VACCINE | 2002年 / 20卷 / 15期

关键词：

mucosal challenged; multiprotein; heterologous prime; boost;

D O I：

10.1016/S0264-410X(02)00076-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here, we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a Rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These highly promising findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：1949 / 1955

页数：7

共 14 条

[1] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

Miller, J ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

SCIENCE, 2001, 292 (5514) :69-74

[2] Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].

Barouch, DH ;

Santra, S ;

Schmitz, JE ;

Kuroda, MJ ;

Fu, TM ;

Wagner, W ;

Bilska, M ;

Craiu, A ;

Zheng, XX ;

Krivulka, GR ;

Beaudry, K ;

Lifton, MA ;

Nickerson, CE ;

Trigona, WL ;

Punt, K ;

Freed, DC ;

Guan, LM ;

Dubey, S ;

Casimiro, D ;

Simon, A ;

Davies, ME ;

Chastain, M ;

Strom, TB ;

Gelman, RS ;

Montefiori, DC ;

Lewis, MG ;

Emini, EA ;

Shiver, JW ;

Letvin, NL .

SCIENCE, 2000, 290 (5491) :486-492

[3] Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection [J].

Egan, MA ;

Charini, WA ;

Kuroda, MJ ;

Schmitz, JE ;

Racz, P ;

Tenner-Racz, K ;

Manson, K ;

Wyand, M ;

Lifton, MA ;

Nickerson, CE ;

Fu, TM ;

Shiver, JW ;

Letvin, NL .

JOURNAL OF VIROLOGY, 2000, 74 (16) :7485-7495

[4]

Goulder PJR, 1999, AIDS, V13, pS121

[5] Characterization of molecularly cloned simian human immunodeficiency viruses causing rapid CD4(+) lymphocyte depletion in rhesus monkeys [J].

Karlsson, GB ;

Halloran, M ;

Li, J ;

Park, IW ;

Gomila, R ;

Reimann, KA ;

Axthelm, MK ;

Iliff, SA ;

Letvin, NL ;

Sodroski, J .

JOURNAL OF VIROLOGY, 1997, 71 (06) :4218-4225

[6] Analysis of successful immune responses in persons infected with hepatitis C virus [J].

Lechner, F ;

Wong, DKH ;

Dunbar, PR ;

Chapman, R ;

Chung, RT ;

Dohrenwend, P ;

Robbins, G ;

Phillips, R ;

Klenerman, P ;

Walker, BD .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (09) :1499-1512

[7] Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [J].

Mellors, JW ;

Rinaldo, CR ;

Gupta, P ;

White, RM ;

Todd, JA ;

Kingsley, LA .

SCIENCE, 1996, 272 (5265) :1167-1170

[8] EVALUATION OF ANTIVIRAL DRUGS AND NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS BY A RAPID AND SENSITIVE MICROTITER INFECTION ASSAY [J].

MONTEFIORI, DC ;

ROBINSON, WE ;

SCHUFFMAN, SS ;

MITCHELL, WM .

JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (02) :231-235

[9] Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1 [J].

Montefiori, DC ;

Reimann, KA ;

Wyand, MS ;

Manson, K ;

Lewis, MG ;

Collman, RG ;

Sodroski, JG ;

Bolognesi, DP ;

Letvin, NL .

JOURNAL OF VIROLOGY, 1998, 72 (04) :3427-3431

[10] Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV [J].

Ourmanov, I ;

Brown, CR ;

Moss, B ;

Carroll, M ;

Wyatt, L ;

Pletneva, L ;

Goldstein, S ;

Venzon, D ;

Hirsch, VM .

JOURNAL OF VIROLOGY, 2000, 74 (06) :2740-2751

← 1 2 →